AR022395A1 - PEPTIDOS QUE ACTUAN COMO INHIBIDORES DE LA INTEGRINA ALFAvBETA6, LOS MEDICAMENTOS A BASE DE ESTOS PEPTIDOS, LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN AL MENOS UNO DE ESTOS PEPTIDOS, EL EMPLEO DE ESTOS PEPTIDOS PARA PREPARAR UN MEDICAMENTO, SECUENCIAS DE ADN RECOMBINANTE QUE CODIFICAN PARA UN FRA - Google Patents
PEPTIDOS QUE ACTUAN COMO INHIBIDORES DE LA INTEGRINA ALFAvBETA6, LOS MEDICAMENTOS A BASE DE ESTOS PEPTIDOS, LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN AL MENOS UNO DE ESTOS PEPTIDOS, EL EMPLEO DE ESTOS PEPTIDOS PARA PREPARAR UN MEDICAMENTO, SECUENCIAS DE ADN RECOMBINANTE QUE CODIFICAN PARA UN FRAInfo
- Publication number
- AR022395A1 AR022395A1 ARP990106525A ARP990106525A AR022395A1 AR 022395 A1 AR022395 A1 AR 022395A1 AR P990106525 A ARP990106525 A AR P990106525A AR P990106525 A ARP990106525 A AR P990106525A AR 022395 A1 AR022395 A1 AR 022395A1
- Authority
- AR
- Argentina
- Prior art keywords
- peptides
- prepare
- integrin
- formula
- leu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19858857 | 1998-12-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR022395A1 true AR022395A1 (es) | 2002-09-04 |
Family
ID=7891834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990106525A AR022395A1 (es) | 1998-12-19 | 1999-12-17 | PEPTIDOS QUE ACTUAN COMO INHIBIDORES DE LA INTEGRINA ALFAvBETA6, LOS MEDICAMENTOS A BASE DE ESTOS PEPTIDOS, LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN AL MENOS UNO DE ESTOS PEPTIDOS, EL EMPLEO DE ESTOS PEPTIDOS PARA PREPARAR UN MEDICAMENTO, SECUENCIAS DE ADN RECOMBINANTE QUE CODIFICAN PARA UN FRA |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1140989A1 (de) |
JP (1) | JP2002533064A (de) |
CN (1) | CN1335853A (de) |
AR (1) | AR022395A1 (de) |
BR (1) | BR9916323A (de) |
CA (1) | CA2355874A1 (de) |
CZ (1) | CZ20012212A3 (de) |
NO (1) | NO20013013D0 (de) |
WO (1) | WO2000037487A1 (de) |
ZA (1) | ZA200105929B (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19929410A1 (de) * | 1999-06-26 | 2000-12-28 | Merck Patent Gmbh | Inhibitoren des Integrins avß6 |
DE19933173A1 (de) * | 1999-07-15 | 2001-01-18 | Merck Patent Gmbh | Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
US20090028853A1 (en) * | 2006-10-19 | 2009-01-29 | The Regents Of The University Of California, A California Corporation | TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN ALPHAvBETA6 |
NZ535425A (en) | 2002-03-13 | 2008-05-30 | Biogen Idec Inc | Anti-alphavbeta6 antibodies |
MXPA05008313A (es) * | 2003-02-06 | 2005-09-20 | Merck Patent Gmbh | Sulfonamidas peptidicas. |
CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
GB0520068D0 (en) | 2005-10-03 | 2005-11-09 | Cancer Res Technology | av peptide ligand |
AU2007272995B2 (en) | 2006-07-10 | 2013-02-07 | Biogen Idec Ma Inc. | Compositions and methods for inhibiting growth of smad4-deficient cancers |
TW200815474A (en) | 2006-08-03 | 2008-04-01 | Astrazeneca Ab | Antibodies alphaVbeta6 and uses thereof |
WO2009093251A2 (en) * | 2008-01-24 | 2009-07-30 | Gavish-Galilee Bio Applications Ltd | Reovirus vaccine based on sigma c protein sequence |
EP2870170B1 (de) * | 2012-07-03 | 2017-09-06 | Il Yang Pharm. Co., Ltd. | Neuartige peptide und verwendungen davon |
WO2014144466A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
WO2014143739A2 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
RU2769702C2 (ru) | 2017-02-28 | 2022-04-05 | Морфик Терапьютик, Инк. | Ингибиторы интегрина avb6 |
MA47692A (fr) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
MX2021002181A (es) | 2018-08-29 | 2021-07-15 | Morphic Therapeutic Inc | Inhibicion de la integrina alfa v beta 6. |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ219515A (en) * | 1987-02-10 | 1989-09-27 | Wellcome Found | Fusion proteins comprising influenza virus ha and a nonnatural antigenic epitope |
-
1999
- 1999-12-11 JP JP2000589556A patent/JP2002533064A/ja active Pending
- 1999-12-11 WO PCT/EP1999/009842 patent/WO2000037487A1/de not_active Application Discontinuation
- 1999-12-11 CZ CZ20012212A patent/CZ20012212A3/cs unknown
- 1999-12-11 CN CN99814760A patent/CN1335853A/zh active Pending
- 1999-12-11 BR BR9916323-3A patent/BR9916323A/pt not_active IP Right Cessation
- 1999-12-11 EP EP99963507A patent/EP1140989A1/de not_active Withdrawn
- 1999-12-11 CA CA002355874A patent/CA2355874A1/en not_active Abandoned
- 1999-12-17 AR ARP990106525A patent/AR022395A1/es not_active Application Discontinuation
-
2001
- 2001-06-18 NO NO20013013A patent/NO20013013D0/no not_active Application Discontinuation
- 2001-07-18 ZA ZA200105929A patent/ZA200105929B/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR9916323A (pt) | 2001-10-30 |
NO20013013L (no) | 2001-06-18 |
EP1140989A1 (de) | 2001-10-10 |
WO2000037487A1 (de) | 2000-06-29 |
NO20013013D0 (no) | 2001-06-18 |
JP2002533064A (ja) | 2002-10-08 |
ZA200105929B (en) | 2003-03-18 |
CN1335853A (zh) | 2002-02-13 |
CA2355874A1 (en) | 2000-06-29 |
WO2000037487A8 (de) | 2001-03-29 |
CZ20012212A3 (cs) | 2001-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR022395A1 (es) | PEPTIDOS QUE ACTUAN COMO INHIBIDORES DE LA INTEGRINA ALFAvBETA6, LOS MEDICAMENTOS A BASE DE ESTOS PEPTIDOS, LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN AL MENOS UNO DE ESTOS PEPTIDOS, EL EMPLEO DE ESTOS PEPTIDOS PARA PREPARAR UN MEDICAMENTO, SECUENCIAS DE ADN RECOMBINANTE QUE CODIFICAN PARA UN FRA | |
Chorev et al. | Recent developments in retro peptides and proteins—an ongoing topochemical exploration | |
ES2359616T3 (es) | Péptidos citotóxicos modificados por restos voluminosos o lipofílicos. | |
ES2346771T3 (es) | Peptidos con multiples dominios a-helicoidales anfipaticos y procedimientos para su uso. | |
ES2277676T3 (es) | Antagonistas de los peptidos glp-2 intestinotroficos. | |
DK0950096T3 (da) | Anti-invasive og anti-angiogene urokinase-fragmenter og deres anvendelse | |
ES2406090T3 (es) | Péptidos que tienen actividad farmacológica para tratar los trastornos asociados con la alteración de la migración celular, tal como el cáncer | |
ES2544573T3 (es) | Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor | |
BRPI0619399A2 (pt) | derivado de metastina ou um sal do mesmo, composto ou um sal do mesmo, prà-droga, medicamento, e, uso de uma dose eficaz do derivado de metastina | |
EA021222B1 (ru) | Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro | |
ES2427171T3 (es) | Tratamiento de infecciones fúngicas y/o protistas | |
BRPI0207502B1 (pt) | compostos, enanciômeros, composição farmacêutica, uso de compostos, e, processo para a fabricação de compostos | |
UY23561A1 (es) | Procedimiento para la preparacion de tnf-muteinas | |
EA011037B1 (ru) | Олигомерные пептиды и их применение для лечения вич инфекций | |
AR003121A1 (es) | Antagonistas del receptor de adhesión, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y su empleo para preparar medicamentos y combatir enfermedades | |
ES2323963T3 (es) | Peptido y/o proteinas y su uso para la fabricacion de un medicamento terapeutico y/o preventivo. | |
PH12020551118A1 (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
US7393824B1 (en) | Methods of peptide preparation | |
JP2011523634A (ja) | ペプチド、ペプチド模倣物およびそれらの誘導体、それらの製造、ならびに治療および/または予防活性のある医薬組成物を調製するためのそれらの使用 | |
US20080171697A1 (en) | Peptides Having For Example Antiangiogenic Activity and Applications Thereof In Therapeutics | |
Čemažar et al. | Oxidative folding of cyclic cystine knot proteins | |
ATE177843T1 (de) | Peptomere mit erhöhter immunogenizität | |
JP2018526987A (ja) | 腫瘍抑制ペプチド | |
AR010924A1 (es) | Azapeptidos ciclicos, sus enantiomeros y diastereomeros, un procedimiento para su preparacion, su empleo para preparar un medicamento, las preparacionesfarmaceuticas que los contienen y un procedimiento para obtener estas preparaciones farmaceuticas. | |
AR020101A1 (es) | Un antagonista peptido del receptor de uroquinasa humana, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y metodopara seleccionar un antagonista peptido adecuado. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |